High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
暂无分享,去创建一个
Joshua M. Korn | Derek Y. Chiang | Tara L. Naylor | Angad P. Singh | J. Lehár | W. Sellers | Yan Tang | J. Korn | K. Venkatesan | R. Leary | Anupama Reddy | J. Monahan | P. Atadja | C. Schnell | E. Li | Alice T. Loo | A. Kauffmann | H. Bitter | D. Ruddy | Hui Gao | S. Ferretti | Youzhen Wang | Mallika Singh | Chao Zhang | Guizhi Yang | Yun Zhang | O. A. Balbin | S. Barbe | H. Cai | F. Casey | S. Chatterjee | S. Chuai | S. Cogan | S. Collins | Ernesta Dammassa | N. Ebel | M. Embry | John Green | C. Kowal | Ying Liang | Edward G. Lorenzana | E. McDonald | M. Mclaughlin | J. Merkin | R. Meyer | M. Patawaran | Claudia Röelli | Fernando Salangsang | F. Santacroce | A. Singh | W. Tinetto | Sonja Tobler | Roberto Velazquez | F. V. Arx | H. Wang | Zongyao Wang | M. Wiesmann | D. Wyss | Fiona Xu | E. Lees | F. Hofmann | N. Keen | R. Cozens | M. Jensen | N. Pryer | J. Williams | Fabian Von Arx | J. Green | H. Gao | Hui Wang | Hui Gao | E. Robert McDonald | Shawn Cogan | John E Monahan | O Alejandro Balbin | Derek Y Chiang | Scott D Collins | Rebecca J Leary | Margaret E McLaughlin | Tara L Naylor | Angad P Singh | Hui Qin Wang
[1] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[2] M Van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.
[3] T. Curran,et al. Shh pathway activity is down-regulated in cultured medulloblastoma cells: implications for preclinical studies. , 2006, Cancer research.
[4] Susan E. Abbatiello,et al. Erratum: Synergistic drug combinations tend to improve therapeutically relevant selectivity , 2009, Nature Biotechnology.
[5] Richard Durbin,et al. Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .
[6] M. DePristo,et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.
[7] Charles C. Persinger,et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.
[8] Joshua F. McMichael,et al. Genome Remodeling in a Basal-like Breast Cancer Metastasis and Xenograft , 2010, Nature.
[9] Michael Krauthammer,et al. PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells , 2010, Pigment cell & melanoma research.
[10] A. Ashworth,et al. Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation , 2010, British Journal of Cancer.
[11] Mark T. W. Ebbert,et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes , 2011, Nature Medicine.
[12] M. DePristo,et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.
[13] J. Arrowsmith. Trial watch: Phase II failures: 2008–2010 , 2011, Nature Reviews Drug Discovery.
[14] John Quackenbush,et al. Exome sequencing-based copy-number variation and loss of heterozygosity detection: ExomeCNV , 2011, Bioinform..
[15] L. Cope,et al. Promoter Methylation in Head and Neck Squamous Cell Carcinoma Cell Lines Is Significantly Different than Methylation in Primary Tumors and Xenografts , 2011, PloS one.
[16] A. Aplin,et al. Hyperactivation of MEK–ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells , 2011, Oncogene.
[17] Davide Corà,et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. , 2011, Cancer discovery.
[18] J. Meyerhardt,et al. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. , 2011, The Journal of clinical investigation.
[19] K. Flaherty,et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.
[20] Philippe Dessen,et al. Characterization of a Large Panel of Patient-Derived Tumor Xenografts Representing the Clinical Heterogeneity of Human Colorectal Cancer , 2012, Clinical Cancer Research.
[21] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[22] Aik Choon Tan,et al. Patient-derived tumour xenografts as models for oncology drug development , 2012, Nature Reviews Clinical Oncology.
[23] S. Nelson,et al. Melanoma whole exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance , 2012, Nature Communications.
[24] Yu Shyr,et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.
[25] Pablo Cingolani,et al. © 2012 Landes Bioscience. Do not distribute. , 2022 .
[26] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[27] A. Bardelli,et al. Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas , 2012, Clinical Cancer Research.
[28] Julian Downward,et al. Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer. , 2013, Cancer discovery.
[29] W. Sellers,et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance , 2013, Nature.
[30] G. Hannon,et al. Patient-derived tumor xenografts: transforming clinical samples into mouse models. , 2013, Cancer research.
[31] Joshua M. Korn,et al. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). , 2013, Cancer discovery.
[32] J M Reichert,et al. Clinical Approval Success Rates for Investigational Cancer Drugs , 2013, Clinical pharmacology and therapeutics.
[33] D. Schadendorf,et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] J. Arrowsmith,et al. Trial Watch: Phase II and Phase III attrition rates 2011–2012 , 2013, Nature Reviews Drug Discovery.
[35] H. Selby,et al. Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models , 2013, Clinical Cancer Research.
[36] Steven A. Roberts,et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .
[37] D. Stover,et al. Molecular characterization of patient-derived human pancreatic tumor xenograft models for preclinical and translational development of cancer therapeutics. , 2013, Neoplasia.
[38] G. Adolf,et al. Pharmacodynamic and Antineoplastic Activity of BI 836845, a Fully Human IGF Ligand-Neutralizing Antibody, and Mechanistic Rationale for Combination with Rapamycin , 2013, Molecular Cancer Therapeutics.
[39] Marcela Dávila López,et al. Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions , 2014, Oncotarget.
[40] Antoni Ribas,et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. , 2014, Cancer discovery.
[41] J. Baselga,et al. Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial , 2014, Clinical Cancer Research.
[42] Dennis C. Friedrich,et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. , 2014, Cancer discovery.
[43] R. Berger,et al. A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours , 2014, British Journal of Cancer.
[44] D. Erdmann,et al. Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials , 2014, Molecular Cancer Therapeutics.
[45] Manuel Hidalgo,et al. Patient-derived xenograft models: an emerging platform for translational cancer research. , 2014, Cancer discovery.
[46] Judy Lucas,et al. Advances in patient-derived tumor xenografts: from target identification to predicting clinical response rates in oncology. , 2014, Biochemical pharmacology.
[47] F. Shepherd,et al. Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial , 2014, Experimental Hematology & Oncology.
[48] G. Pupo,et al. BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact , 2014, Clinical Cancer Research.
[49] Sohrab P. Shah,et al. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution , 2014, Nature.
[50] K. Papadopoulos,et al. Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor , 2015, Cancer Chemotherapy and Pharmacology.
[51] Obi L. Griffith,et al. Convergent loss of PTEN leads to clinical resistance to a PI3Kα inhibitor , 2014, Nature.
[52] G. Scagliotti,et al. Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[53] A. Hauschild,et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.